Return to Listing

5 result(s) for Taxotere

PI Name Protocol # Title
Tomasz Beer IRB00005688 A Phase II study of MAOA inhibitor plus docetaxel in patients receiving and progressing on docetaxel therapy
Tomasz Beer IRB00010479 A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
Jeremy Cetnar IRB00011046 S1400: Lung-MAP, Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
Khaled Tolba IRB00012012 A Phase III, Open-Label, Randomized Study To Investigate The Efficacy And Safety Of MPDL3280A (ANTI−PD-L1 ANTIBODY) Compared With Best Supportive Care Following adjuvant Cisplatin-Based Chemotherapy In PD-L1−Selected Patients With Completely Resected STAGE IB−IIIA
Gina Vaccaro STUDY00015439 A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)

You may also qualify for Phase 1 Program trials.

For more information:
Call: 503-494-1080